Summary
This prediction ended on 17.10.18 with a price of €1.16. The BUY prediction by Quitte finished with a performance of 13.16%. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Vical Inc | - | - | - | - |
| iShares Core DAX® | 1.085% | -0.846% | 12.464% | 58.472% |
| iShares Nasdaq 100 | -1.665% | -3.306% | 1.502% | 84.473% |
| iShares Nikkei 225® | 3.863% | 6.308% | 22.272% | 56.185% |
| iShares S&P 500 | 0.111% | -1.337% | 1.101% | 58.320% |
Comments by Quitte for this prediction
In the thread Vical Inc diskutieren
Zock auf failed
In a press release issued early this morning, the company announced top-line results from its Phase 2 clinical study of bivalent. Bivalent was designed as a candidate for the treatment of herpes simplex virus type 2 (HSV-2). Unfortunately, the study did not meet its primary enpdoint of annualized lesion recurrence rate. This endpoint was calculated based on those genital recurrences that were both clincially- and virologically-confirmed during a minimum of nine months of surveillance.
https://seekingalpha.com/article/4181071-vical-compelling-reason-buy